切利尼布通过向DRP-1诱导甲状腺癌细胞中的线粒体分裂
Dongguang Qin1, Wei Ding1, Xuesong Wu1
1Department of Head and Neck Surgery, Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China.
切利尼布通过激活 mitochondrial Calcium Uniporter (MCU) /calpain 途径来破坏甲状腺癌细胞中的线粒体动力学,从而导致细胞功能障碍. 这揭示了切利尼尼在治疗甲状腺癌中的新治疗机制.
科学领域:
- 线粒体生物学 线粒体生物学
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 线粒体动力学对甲状腺癌的进展至关重要,它会影响亡,新陈代谢和氧化应激.
- 铁氨酸激酶抑制剂 (Ceritinib) 已显示出抗癌潜力,但其对甲状腺癌线粒体功能的影响尚不清楚.
研究的目的:
- 为了研究切利尼尼对TPC-1甲状腺癌细胞中线粒体功能的影响.
- 阐明基底的分子机制的赛里替尼对线粒体的作用.
主要方法:
- 评估了细胞活力 (CCK-8试验) 和细胞毒性 (LDH释放试验).
- 测量了线粒体反应性氧物种 (ROS) 和8-基二氧化甘氨酸 (8-OHdG) 水平.
- 分析了线粒体形态,基因表达 (实时PCR) 和蛋白质水平 (西式涂抹).
主要成果:
- 谢里替尼诱导了线粒体的氧化应激,提高了ROS和8-OHdG,并抑制了超氧化物脱酶 (Mn-SOD) 活性.
- 线粒体呼吸,ATP生产和复合III活动受损,表明功能障碍.
- 切利尼布通过线粒体单载体 (MCU) /calpain/dynamin相关蛋白1 (Drp1) 轴促进了线粒体的分裂.
结论:
- 切利尼布通过MCU/calpain/Drp1通路破坏甲状腺癌细胞中的线粒体动力学.
- 这项研究揭示了甲状腺癌中塞里尼布的新机制,表明其作为治疗策略的潜力.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:14Assessment of Mitochondrial Fission/Fusion Dynamics in Kidney Proximal Tubular Cells
Published on: November 14, 2025
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway
Drugs that Destabilize Microtubules
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
